Latest Rhenman & Partners Asset Management AB Stock Portfolio

Rhenman & Partners Asset Management AB Performance:
2025 Q1: 0.04%YTD: 0.04%2024: 6.24%

Performance for 2025 Q1 is 0.04%, and YTD is 0.04%, and 2024 is 6.24%.

About Rhenman & Partners Asset Management AB and 13F Hedge Fund Stock Holdings

In it's latest 13F Holdings report, Rhenman & Partners Asset Management AB reported an equity portfolio of $870 Millions as of 31 Mar, 2025.

The top stock holdings of Rhenman & Partners Asset Management AB are UNH, LLY, VRTX. The fund has invested 4.7% of it's portfolio in UNITED HEALTH GROUP INC and 4% of portfolio in LILLY ELI & CO.

The fund managers got completely rid off INTRA-CELLULAR THERAPIES INC (ITCI), STRYKER CORPORATION (SYK) and UNIVERSAL HLTH SVCS INC (UHS) stocks. They significantly reduced their stock positions in INSPIRE MED SYS INC (INSP), MERCK & CO. INC (MRK) and APELLIS PHARMACEUTICALS INC (APLS). Rhenman & Partners Asset Management AB opened new stock positions in BRISTOL-MYERS SQUIBB CO (BMY), DEXCOM INC (DXCM) and ANTERIS TECHNOLOGIES GLOBAL. The fund showed a lot of confidence in some stocks as they added substantially to GLAUKOS CORP (GKOS), INSMED INC (INSM) and ALNYLAM PHARMACEUTICALS INC (ALNY).

Rhenman & Partners Asset Management AB Annual Return Estimates Vs S&P 500

Our best estimate is that Rhenman & Partners Asset Management AB made a return of 0.04% in the last quarter. In trailing 12 months, it's portfolio return was -2.95%.
2019202020212022202320242025−2002040Performance (%)PerformanceS&P 500

New Buys

Ticker$ Bought
bristol-myers squibb co19,821,800
dexcom inc10,585,000
anteris technologies global4,695,600
verona pharma plc4,444,300
akero therapeutics inc3,744,400
ultragenyx pharmaceutical inc2,969,220
moonlake immunotherapeutics1,758,150
denali therapeutics inc1,359,500

New stocks bought by Rhenman & Partners Asset Management AB

Additions to existing portfolio by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB reduced stake in above stock

Sold off

Ticker$ Sold
intra-cellular therapies inc-14,699,500
igm biosciences inc-770,251
pliant therapeutics inc-1,531,010
novo-nordisk a s-4,301,000
transmedics group inc-2,369,300
universal hlth svcs inc-5,544,080
stryker corporation-8,101,120
charles riv labs intl inc-2,741,310

Rhenman & Partners Asset Management AB got rid off the above stocks

Sector Distribution

Rhenman & Partners Asset Management AB has about 97.4% of it's holdings in Healthcare sector.

97%
Sector%
Healthcare97.4
Others2.5

Market Cap. Distribution

Rhenman & Partners Asset Management AB has about 73.2% of it's portfolio invested in the large-cap and mega-cap stocks.

61%19%12%
Category%
LARGE-CAP61.4
MID-CAP18.5
MEGA-CAP11.8
SMALL-CAP6.6
UNALLOCATED1.6

Stocks belong to which Index?

About 79.4% of the stocks held by Rhenman & Partners Asset Management AB either belong to S&P 500 or RUSSELL 2000 index.

58%22%21%
Index%
S&P 50057.6
RUSSELL 200021.8
Others20.5
Top 5 Winners (%)%
INMB
inmune bio inc
67.2 %
ALHC
alignment healthcare inc
57.7 %
CVS
cvs health corp
50.4 %
AXSM
axsome therapeutics inc
38.1 %
RPRX
royalty pharma plc
22.8 %
Top 5 Winners ($)$
ALHC
alignment healthcare inc
11.4 M
CVS
cvs health corp
6.0 M
BSX
boston scientific corp
5.1 M
GILD
gilead sciences inc
4.9 M
MCK
mckesson corp
4.5 M
Top 5 Losers (%)%
ARVN
arvinas inc
-63.0 %
ANNX
annexon inc
-59.8 %
XNCR
xencor inc
-53.7 %
GERN
geron corp
-49.1 %
JANX
janux therapeutics inc
-46.8 %
Top 5 Losers ($)$
PRCT
procept biorobotics corp
-9.5 M
GKOS
glaukos corp
-8.3 M
EXAS
exact sciences corp
-5.9 M
JANX
janux therapeutics inc
-4.3 M
IOVA
iovance biotherapeutics inc
-3.7 M

Rhenman & Partners Asset Management AB Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

UNHLLYVRTXMCKBSXGKOSGILDPRCTISRGALHCMDTMOHELVREGNCOOBMYNTRAEXASBMRNABBVTHCPODDCVSJAZZINSMOSCRALNYRPRXAXSMHUMDXCMNBIXZBHCIABCDHRCN..DV..TGTXABTBIIBALGNTM..HC..SN....AM..V..B..CYTK

Current Stock Holdings of Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB has 94 stocks in it's portfolio. About 34.3% of the portfolio is in top 10 stocks. PRCT proved to be the most loss making stock for the portfolio. ALHC was the most profitable stock for Rhenman & Partners Asset Management AB last quarter.

Last Reported on: 14 May, 2025
TickerNamesorted descending% PortfolioShares Held$ ValueType% ChangeOptions

Historical Trend of UNITED HEALTH GROUP INC Position Held By Rhenman & Partners Asset Management AB

What % of Portfolio is UNH?:

Number of UNH shares held:

Change in No. of Shares Held: